Anna Eshoo: “I mean, that is a pittance. I mean, once that is used by a handful of organizations, then what happens?”

I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.

The Medicaid Value-Based Payments for Patients Act will codify a CMS rule to help ensure Medicaid enrollees have access to breakthrough gene therapies.

This is, as you said and have said many times, this is a devastating disease, and I don't think this can be treated as 17 months of a little additional hope.

You did a great job, and I think that you answered--with your answers you were highly instructive to all of the members of the committee.